These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 35103338)
1. Contrast-Enhanced Ultrasound Features of Adult Xp11.2 Translocation Renal Cell Carcinoma: Differential Diagnosis With Three Main Renal Cell Carcinoma Subtypes. Ma W; Zhang F; Huang H; Wang W; Zhu Y; Lu Y; Guo H; Gan W J Ultrasound Med; 2022 Nov; 41(11):2673-2685. PubMed ID: 35103338 [TBL] [Abstract][Full Text] [Related]
2. Contrast-enhanced ultrasound findings of adult renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma. Wei S; Tian F; Xia Q; Huang P; Zhang Y; Xia Z; Wu M; Yang B Cancer Imaging; 2019 Dec; 20(1):1. PubMed ID: 31892340 [TBL] [Abstract][Full Text] [Related]
3. The value of real-time contrast-enhanced ultrasound combined with CT enhancement in the differentiation of subtypes of renal cell carcinoma. Liang RX; Wang H; Zhang HP; Ye Q; Zhang Y; Zheng MJ; Xue ES; Zhu YF Urol Oncol; 2021 Dec; 39(12):837.e19-837.e28. PubMed ID: 34654644 [TBL] [Abstract][Full Text] [Related]
4. Papillary renal cell carcinoma and clear cell renal cell carcinoma: Differentiation of distinct histological types with contrast - enhanced ultrasonography. Xue LY; Lu Q; Huang BJ; Li Z; Li CX; Wen JX; Wang WP Eur J Radiol; 2015 Oct; 84(10):1849-56. PubMed ID: 26149528 [TBL] [Abstract][Full Text] [Related]
5. Dynamic Contrast-Enhanced CT Characterization of Xp11.2 Translocation/TFE3 Gene Fusions versus Papillary Renal Cell Carcinomas. He J; Zhou K; Zhu B; Zhang G; Li X; Guo H; Gan W; Zhou Z; Liu T Biomed Res Int; 2015; 2015():298679. PubMed ID: 26636097 [TBL] [Abstract][Full Text] [Related]
6. Differentiation of subtypes of renal cell carcinoma with contrast-enhanced ultrasonography. Xue LY; Lu Q; Huang BJ; Li CX; Yan LX; Wang WP Clin Hemorheol Microcirc; 2016 Oct; 63(4):361-371. PubMed ID: 26598999 [TBL] [Abstract][Full Text] [Related]
7. MicroRNA-204-5p: A novel candidate urinary biomarker of Xp11.2 translocation renal cell carcinoma. Kurahashi R; Kadomatsu T; Baba M; Hara C; Itoh H; Miyata K; Endo M; Morinaga J; Terada K; Araki K; Eto M; Schmidt LS; Kamba T; Linehan WM; Oike Y Cancer Sci; 2019 Jun; 110(6):1897-1908. PubMed ID: 31006167 [TBL] [Abstract][Full Text] [Related]
8. Both SUMOylation and ubiquitination of TFE3 fusion protein regulated by androgen receptor are the potential target in the therapy of Xp11.2 translocation renal cell carcinoma. Liu N; Chen Y; Yang L; Shi Q; Lu Y; Ma W; Han X; Guo H; Li D; Gan W Clin Transl Med; 2022 Apr; 12(4):e797. PubMed ID: 35452181 [TBL] [Abstract][Full Text] [Related]
10. Papillary renal cell carcinoma in contrast-enhanced ultrasound (CEUS) - A diagnostic performance study. Mueller-Peltzer K; Negrao de Figueiredo G; Graf T; Rübenthaler J; Clevert DA Clin Hemorheol Microcirc; 2019; 71(2):159-164. PubMed ID: 30562896 [TBL] [Abstract][Full Text] [Related]
11. Role of Contrast-Enhanced Ultrasound With the Enhancement Pattern and Qualitative Analysis for Differentiating Hypovascular Solid Renal Lesions. Li J; Huang X; Wang L; Wang X; Li Y; Liu X; Ye N; Yang S; Nie F Ultrasound Med Biol; 2024 Feb; 50(2):295-303. PubMed ID: 37996360 [TBL] [Abstract][Full Text] [Related]
12. Dynamic Computed Tomographic Features of Adult Renal Cell Carcinoma Associated With Xp11.2 Translocation/TFE3 Gene Fusions: Comparison With Clear Cell Renal Cell Carcinoma. He J; Gan W; Liu S; Zhou K; Zhang G; Guo H; Zhu B J Comput Assist Tomogr; 2015; 39(5):730-6. PubMed ID: 25955396 [TBL] [Abstract][Full Text] [Related]
13. Newly designed break-apart and ASPL-TFE3 dual-fusion FISH assay are useful in diagnosing Xp11.2 translocation renal cell carcinoma and ASPL-TFE3 renal cell carcinoma: a STARD-compliant article. Chen X; Yang Y; Gan W; Xu L; Ye Q; Guo H Medicine (Baltimore); 2015 May; 94(19):e873. PubMed ID: 25984679 [TBL] [Abstract][Full Text] [Related]
14. Preoperative neutrophil-to-lymphocyte ratio predicts the surgical outcome of Xp11.2 translocation/TFE3 renal cell carcinoma patients. Agizamhan S; Qu F; Liu N; Sun J; Xu W; Zhang L; Guo H; Gan W BMC Urol; 2018 Jun; 18(1):60. PubMed ID: 29890986 [TBL] [Abstract][Full Text] [Related]
15. NMRK2 is an efficient diagnostic indicator for Xp11.2 translocation renal cell carcinoma. Feng H; Cao S; Fu S; Liu J; Gao Y; Dong Z; Cai T; Wen L; Xiong Z; Li S; Zhang X; Ma X; Li X J Pathol; 2024 Oct; 264(2):228-240. PubMed ID: 39092712 [TBL] [Abstract][Full Text] [Related]
16. MDCT findings of renal cell carcinoma associated with Xp11.2 translocation and TFE3 gene fusion and papillary renal cell carcinoma. Woo S; Kim SY; Lee MS; Moon KC; Kim SH; Cho JY; Kim SH AJR Am J Roentgenol; 2015 Mar; 204(3):542-9. PubMed ID: 25714283 [TBL] [Abstract][Full Text] [Related]
18. [Differential diagnosis between renal cell carcinoma associated with XP11.2 translocation/TFE gene fusion and papillary renal cell carcinoma based on CT and MRI findings]. Zhu Q; Zhu W; Wu J; Fu J; Chen W; Wang Z Zhonghua Yi Xue Za Zhi; 2014 May; 94(19):1470-2. PubMed ID: 25143166 [TBL] [Abstract][Full Text] [Related]
19. The Value of Contrast-Enhanced Ultrasound in Diagnosing Small Renal Cell Carcinoma Subtypes and Angiomyolipoma. Cao H; Fang L; Chen L; Zhan J; Diao X; Liu Y; Lu C; Zhang Z; Chen Y J Ultrasound Med; 2022 Jun; 41(6):1415-1423. PubMed ID: 34499770 [TBL] [Abstract][Full Text] [Related]
20. Incidence and significance of psammoma bodies in Xp11.2 translocation renal cell carcinoma and papillary renal cell carcinoma. Liu N; Qu F; Wei K; Gan W; Wang Z; Zhuang W; Agizamhan S; Ma W; Yang J; Chen M; Xu L; Guo H; Li D Oncol Lett; 2019 Jul; 18(1):472-478. PubMed ID: 31289519 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]